For information about COVID-19, including symptoms and prevention, please read our COVID-19 patient guide. Please also consider supporting Weill Cornell Medicine’s efforts against the pandemic.
Pathology & Laboratory Medicine

You are here


Dr. Domenick J. Falcone receives two teaching awards

Congratulations to Dr. Domenick J. Falcone who has received two teaching awards during Convocation on May 27, 2015!

Charles L. Bardes, MD Teaching Prize (2015)

The prize was established in 2000 by David and Betty Cooper-Wallerstein, in gratitude for the excellent and compassionate medical care provided by Dr. Bardes to three generations of Cooper-Wallerstein family. The prize is awarded annually to a member of the faculty, who has been an outstanding teacher at Weill Cornell Medical College, demonstrated leadership, dedication, and concern for the students. The recipient is selected by a committee consisting of the Senior Associate Dean for Education, the Associate Dean for Curriculum, and Dr. Bardes.

(L to R) Dr. Barbara L. Hempstead (Senior Associate Dean for Education), Dr. Domenick J. Falcone, Betty Cooper-Wallerstein, Dr. Laurie H. Glimcher (Stephen and Suzanne Weiss Dean of WCMC & Provost for Medical Affairs) and Dr. Charles L. Bardes (Associate Dean for Admissions)

New study describes genomic landscape of castration-resistant prostate cancer

An international collaboration of researchers are advancing precision medicine to men with a common and aggressive form of prostate cancer.

Several scientists from the Edward and Sandra Meyer Cancer Center were part of a Stand Up to Cancer-Prostate Cancer Foundation Dream Team that sequenced the DNA and RNA of tumor biopsy samples from 150 men with metastatic castration resistant prostate cancer, an advanced cancer that has stopped responding to standard hormone-based therapies.

Previous studies have looked at the genomic landscape of clinically localized prostate cancer and found few actionable genomic alterations. This study – published May 21 in Cell -- is the first to focus on this specific subtype clinically, which is difficult to treat because patients nearly always develop resistance to currently available treatments.

Researchers See Promise for Two New Therapies for Mantle Cell Lymphoma After Discovering Why Tumors Can Become Resistant to a Newly Approved Treatment

The medication was so effective in mantle cell lymphoma, an aggressive, incurable cancer, that the Food and Drug Administration named ibrutinib a "breakthrough" drug. The unprecedented response — 68 percent of patients went into partial or complete remission when they took it — gained the agent accelerated approval last November.

But the disease remains a challenge. Researchers, including those at Weill Cornell Medical College who participated in the ibrutinib clinical trial, found that lymphoma cells in the majority of patients who were taking the drug on its own became resistant to it, either quickly or over time. And patients whose disease progressed often saw their tumors grow faster than before.

Selina Chen-Kiang, PhD
Professor of Pathology and Laboratory Medicine
Professor of Microbiology and Immunology

Now a research team led by Weill Cornell Medical College has revealed key insight into why late resistance occurs. And it has shown in preclinical studies that two different drug-treatment strategies may be useful for patients in whom ibrutinib does not work. More than 66,000 new cases of non-Hodgkin's lymphoma are diagnosed in the United States each year, with mantle cell representing an important subset.

The findings, published in Cancer Discovery, have quickly led to a new clinical trial sponsored by the National Cancer Institute. Weill Cornell is recruiting mantle cell lymphoma patients to participate.

Weill Cornell Medicine Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464 Fax: (212) 746-8192